NEW YORK (GenomeWeb News) – DiaGenic today said that it has licensed biomarkers for mild cognitive impairment to drug firm Merz Pharmaceuticals, which will use the biomarkers for recruiting patients for Alzheimer's disease drug trials.
Frankfurt am Main, Germany-based Merz also has an option to license non-exclusive rights to further biomarkers, under terms of the agreement. Financial details and further terms were not disclosed.
"We have already successfully identified biomarkers of prodromal Alzheimer's disease," DiaGenic CEO Erik Christensen said in a statement. "The agreement with Merz will enable us to accelerate our ongoing multicenter study by recruiting additional sites."